Next Article in Journal / Special Issue
A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A
Previous Article in Journal / Special Issue
Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform
Article Menu

Export Article

Open AccessArticle
Vaccines 2015, 3(4), 829-849; doi:10.3390/vaccines3040829

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease

1
Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, 111 Carlton Street, Athens, GA 30602, USA
2
Artificial Cell Technologies Inc., 5 Science Park, Suite 13, New Haven, CT 06511, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Darrell J. Irvine
Received: 28 July 2015 / Revised: 11 September 2015 / Accepted: 6 October 2015 / Published: 12 October 2015
(This article belongs to the Special Issue Nanoparticle-Based Vaccines)
View Full-Text   |   Download PDF [588 KB, uploaded 12 October 2015]   |  

Abstract

Respiratory syncytial virus (RSV) is the single most important cause of serious lower respiratory tract infections in young children; however no effective treatment or vaccine is currently available. Previous studies have shown that therapeutic treatment with a monoclonal antibody (clone 131-2G) specific to the RSV G glycoprotein CX3C motif, mediates virus clearance and decreases leukocyte trafficking to the lungs of RSV-infected mice. In this study, we show that vaccination with layer-by-layer nanoparticles (LbL-NP) carrying the G protein CX3C motif induces blocking antibodies that prevent the interaction of the RSV G protein with the fractalkine receptor (CX3CR1) and protect mice against RSV replication and disease pathogenesis. Peptides with mutations in the CX3C motif induced antibodies with diminished capacity to block G protein-CX3CR1 binding. Passive transfer of these anti-G protein antibodies to mice infected with RSV improved virus clearance and decreased immune cell trafficking to the lungs. These data suggest that vaccination with LbL-NP loaded with the CX3C motif of the RSV G protein can prevent manifestations of RSV disease by preventing the interaction between the G protein and CX3CR1 and recruitment of immune cells to the airways. View Full-Text
Keywords: RSV; G protein; G glycoprotein; vaccine; CX3C; immunity; nanoparticle RSV; G protein; G glycoprotein; vaccine; CX3C; immunity; nanoparticle
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Jorquera, P.A.; Oakley, K.E.; Powell, T.J.; Palath, N.; Boyd, J.G.; Tripp, R.A. Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. Vaccines 2015, 3, 829-849.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top